DBV Technologies is at the forefront of efforts to develop a safe epicutaneous allergy treatment for a number of our most common allergies. One of the most notorious allergies of modern times has to be peanut allergy, which regularly hospitalizes individuals across the world. Sometimes it can even provoke anaphylaxis (a severe allergic reaction), which…
A l’honneur, deux jeunes entreprises françaises particulièrement innovantes, des start-up biotechs qui fabriquent les médicaments de demain : d’un côté Advanced Accelerator Applications (AAA) à la recherche d’une médecine personnalisée, via une approche nucléaire moléculaire ; de l’autre, DBV Technologies, en quête d’un premier traitement véritablement efficace contre les allergies alimentaires, via une approche singulière.
Huge strides are being made in the field of epicutaneous immunotherapy. Click here if you’d like to discover more about the Paris firm that’s leading the charge. Increasing numbers of individuals suffer from one or more allergy. Well-known allergies include foods such as egg, milk and peanuts.
You may not have heard of epicutaneous immunotherapy before, but this technique is likely to become much better known soon through the research work performed by French firm DBV Technologies (http://www.dbv-technologies.com).